Health Equity Drives Small Molecule Strategy At Serna Bio
Serna Bio is using machine learning and RNA biology to create a platform for the discovery of small molecule modulators of RNA. The startup will seek fresh funding in 2024 and is on the hunt for creative biopharma partnerships.
You may also be interested in...
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024.